Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy - Wikidata - wikimedia - TriplyDB

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

http://www.wikidata.org/entity/Q28394869

about

The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Systematic analysis of microRNA targeting impacted by small insertions and deletions in human genome.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma.PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.Koch Institute Symposium on Cancer Immunology and Immunotherapy OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges Immunotherapy for lung cancer.Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.Clinical Development of PD-1 Blockade in Hematologic Malignancies.The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.Distribution of CD4 and CD8 exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

P2860

Q26748691-7A1F47AB-817D-43E3-846D-E582A272BB57 Q27021570-A30F7E8F-90AB-4C57-BE4E-AABFE2944ECB Q27022789-543DA510-976E-4EB4-B9D1-F09777C86105 Q31104377-501CEA31-F500-45DB-A931-F6D804C4C0A5 Q34270064-DB0AD51A-503F-4727-B579-911DF281768F Q34744674-E88A60E0-E9F6-4A9C-9E60-AA2ED49DFAE3 Q34980976-2D5E19FD-1C25-47AC-86ED-C23A53AA2F11 Q35799094-367CA978-E6A9-43A6-AC5C-1934D3440F48 Q36106006-50BB6D9B-0D0A-4CCB-B93C-C7699541496C Q36470331-158590EB-9AC1-4A11-9C47-ACC9794141F8 Q36597479-3AF716DF-7A10-4FAF-8AF4-1EA300ED2AC0 Q36605526-2387CEF8-918C-4B06-B78D-FD7FEBFB84D7 Q36623597-BC006AD5-413D-40F3-B71A-206A49C98F3E Q36640562-6B0856F6-4BEA-4FCE-93FE-38AFB5A0CF3D Q36711049-C0C115F2-3D8B-441D-B95E-02505757A8BD Q36890963-C695F09E-5A6D-498E-BBCC-7175DFD2AC03 Q36892616-65D6674C-27B6-425E-BEE4-06956516C4F3 Q36916365-269AEF7D-669E-4AE3-99E7-CA79B213F94E Q36936462-2EE54063-7B33-4BBB-BF3B-93672CBC46AC Q37046786-8883ADA9-A4D1-4D20-A1D7-C53125A85D4C Q37079133-3CC1551D-7895-45DC-992A-BD7528A495D0 Q37451618-A7D7B934-F30D-412F-928B-C18303376D5F Q37500940-0A754CF3-CD77-4029-8D9F-61A8EEC7F3F3 Q38374889-276A770C-308F-4826-8CC4-9C7D94B8C037 Q38721959-ECC713D7-713D-44C8-9A5C-C833D5A3248D Q38878906-C512DF1D-F8E4-4238-9C52-6F257155D860 Q41916016-6FB9B69A-2E33-42D8-ABB0-3C9241FF5E71 Q41964740-57875273-6F5D-4964-9E51-E3276E2E886F Q42234959-BA0AECC3-A5A1-4359-848A-F5C3D18BBA0B Q47160054-B3C84CA8-9419-4084-A112-1424B584D030 Q48526801-C2DF210D-F6EF-4BBA-8D5D-91B057157091 Q50070938-B1454A25-C440-4118-AA7C-3CD15552B8F9 Q52906171-85872103-BCC8-4C37-9A64-5283A36D510F Q55282202-F8DEC3E3-4BDD-4647-888C-CAA20AE84350 Q57071375-4264F1AC-B947-4163-9432-73FB9A5D8F83 Q57191726-A74BA071-AE89-4F6D-A02A-05C063D61B7F

P2860

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

http://www.wikidata.org/entity/Q28394869

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@ast

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@en

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@nl

type

label

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@ast

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@en

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@nl

prefLabel

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@ast

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@en

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@nl

P1433

Q28394869-E17DFDCF-2274-4557-8FC4-A782AACD1ED0

P1476

Q28394869-A0E594EF-E7F2-49F9-B585-C6CE35DFC5F5

P2093

Q28394869-2A09FA45-3129-4AC7-8C5E-30D03598BCAA

Q28394869-46FE9202-CE79-41BA-8930-67154D00A2AF

Q28394869-6EF1F8D1-BD16-4995-9C55-F5928FCD13E6

Q28394869-9E5ABAC2-3E62-4F5F-AA68-205D4CD795EB

P2860

Q28394869-0064E71C-7E41-4F19-A8E1-107847681FD7

Q28394869-085C08DB-A2DC-4A46-86C0-0CD208EDACFA

Q28394869-0AB2457B-0972-4964-9617-CB47BB64A19D

Q28394869-0EBC6A35-B698-4BC4-BF08-1B6F70FF1E74

Q28394869-1ABFAF9B-68E7-48DD-A7A6-0D707CCA3A8A

Q28394869-1F32450A-450F-437F-BB37-8A2BB5A0874F

Q28394869-251D219C-B51D-4DA7-BB7A-EAB7C482E4D1

Q28394869-272FFE0B-5ACB-4281-B971-972C235FA27B

Q28394869-3272117B-D521-468F-A5FC-F0F4B9BF2F6A

Q28394869-3463AC88-46C9-40A2-9DF1-9A20B9B93092

P304

Q28394869-282146F9-19A0-48FE-81E0-F3EBD7C7161F

P31

Q28394869-76C2B97A-8F03-4447-B45D-B57295C47697

P3181

Q28394869-880A6FC0-F1FC-465E-BF2B-A99F8A75EB55

P407

Q28394869-54FF18D8-2A23-4F93-A022-BD8AAF6E6CA5

P433

Q28394869-7BC2AE05-093A-4AC6-9704-CFB4CEC7CC35

P478

Q28394869-30E6795C-0878-479D-8FE4-F4C55E9CF97C

P50

Q28394869-2192E4D0-5FEA-40CA-921F-1E4B0CE0DD9A

P577

Q28394869-6173A0BB-15AB-4E0D-B050-718D4D30C4A3

P698

Q28394869-2507224E-E638-46DD-9DC8-7834105E08CD

P921

Q28394869-BD7BCB11-D479-4F18-B7A5-879C024FF761

Q28394869-C0E28D13-6829-4C00-AB42-8AF90E91566D

Q28394869-EBFF731D-C409-43DF-B85D-CC60603E50BD

Q28394869-F8C3E778-8833-44D5-A52A-742096BEA107

P932

Q28394869-08E36C6B-629D-4A25-AF7E-FD77EDAA3F2E

P3181

P1433

Yale Journal of Biology and Medicine

P1476

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

@en

P2093

Britt J Sandler

http://www.w3.org/2001/XMLSchema#string

Dallas B Flies

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Mario Sznol

http://www.w3.org/2001/XMLSchema#string

P2860

Relationships between cancer and aging: a multilevel approach

Overview of preventable industrial causes of occupational cancer

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

The PD-1 pathway in tolerance and autoimmunity

The AP-1 transcription factor Batf controls T(H)17 differentiation

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

P304

409-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2341184

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22180678

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

P932

3238327

http://www.w3.org/2001/XMLSchema#string